Ichnos Glenmark Innovation & AbbVie ink exclusive global licensing agreement for ISB 2001: New York Saturday, July 12, 2025, 12:00 Hrs [IST] IGI Therapeutics SA, a wholly owned su ...

Global trade tensions just got a whole lot worse! The US is leading the charge with a slew of new tariff announcements that ...

The stock was the top percentage gainer on the Nifty Pharma index, which traded 0.3% higher compared to a 0.8% loss in the ...

Glenmark Pharmaceuticals' shares surged 10% to an all-time high of ₹2,094 following the announcement of an exclusive ...

Glenmark Pharma's exclusive licensing deal with AbbVie for ISB-2001 could be transformative, offering significant upside ...

Indian equity benchmarks posted a second straight weekly loss, weighed down by uncertainty over a potential U.S. trade ...

The antibody, ISB 2001, is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) ...

CHENNAI: Indian equity indices closed sharply lower on Friday (July 11), marked by a sharp sell-off in the IT sector, renewed ...

Shares of Glenmark Pharmaceuticals Ltd ended 14.51 per cent higher on Friday after the firm announced signing an up to USD 2-billion deal with AbbVie to commmercialise its underdevelopment drug aimed ...

Indian equity benchmarks posted a second straight weekly loss, weighed down by uncertainty over a potential U.S. trade deal ...

The investment landscape is shifting as companies show resilience and innovation, prompting investors to reassess portfolios. AbbVie, Boeing, Oracle, and Joby Aviation mentioned as potential ...